Get the Stockscreener App
28.46
6.47%
1.73
Cue Biopharma Inc stock is traded at $28.46, with a volume of 292.23K.
It is up +6.47% in the last 24 hours and up +33.12% over the past month.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
See More
Previous Close:
$26.73
Open:
$26.29
24h Volume:
292.23K
Relative Volume:
0.42
Market Cap:
$119.54M
Revenue:
$32.73M
Net Income/Loss:
$-19.52M
P/E Ratio:
-5.1488
EPS:
-5.5275
Net Cash Flow:
$-24.61M
1W Performance:
+5.06%
1M Performance:
+33.12%
6M Performance:
+177.39%
1Y Performance:
+44.72%
1-Day Range:
$25.69
$28.70
1-Week Range:
$23.16
$28.95
52-Week Range:
$4.971
$41.42
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
28.46 | 119.54M | 32.73M | -19.52M | -24.61M | -5.5275 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
Cue Biopharma Inc (CUE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cue Biopharma Company Profile & Introduction - Moomoo
Cue Biopharma (NASDAQ: CUE) registers 551,724 pre-funded-warrant shares for resale - Stock Titan
Cue Biopharma Inc (CUE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
[EFFECT] Cue Biopharma, Inc. SEC Filing - Stock Titan
Cue Biopharma Inc (CUE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cue Biopharma Inc (CUE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cue Biopharma Inc (CUE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cue Biopharma Inc (CUE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cue Biopharma Inc (CUE) Institutional Confidence - TradingKey
Cue Biopharma Inc (CUE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CUE Stock On Track For Best Day In History — Why Is Retail Optimistic? - Stocktwits
Cue Biopharma Inc Stock (US22966J1060): Analyst focus after sharp move and oncology pipeline updates - AD HOC NEWS
Cue Biopharma Inc (CUE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CUE Q3 2025 Earnings: Narrower-Than-Expected Loss Highlights Progress in Pre-Revenue StageProfit Announcement - lwvtexas.org
Cue Biopharma (CUE) VP and Principal Accounting Officer files initial Form 3 - Stock Titan
Ray Sumita reports Cue Biopharma (CUE) shares and 109,179-share option - Stock Titan
Breakeven Is Near for Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) - simplywall.st
Breakeven On The Horizon For NanoXplore Inc. (TSE:GRA) - simplywall.st
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
Cue Biopharma (CUE) director awarded 1,626 stock options at $21.90 strike - Stock Titan
Daniel A. Camardo joins Cue Biopharma (CUE) board and files Form 3 - Stock Titan
Cue Biopharma, Inc. - MLQ.ai
CUE stock slips as CEO leaves after just six months in role - MSN
Cue Biopharma (CUE) Narrows Slightly as Stock Holds Near Key Support LevelsMoney Flow Index - newsline.com
Cue Biopharma Inc stock (US22966J1060): Nasdaq-listed immunotherapy developer after reverse split an - AD HOC NEWS
Veru And 2 Other Intriguing Penny Stocks To Watch - simplywall.st
Cue Biopharma Shareholders Approve 2026 Stock Incentive Plan - The Globe and Mail
[Form 4] Cue Biopharma, Inc. Insider Trading Activity - Stock Titan
Cue Biopharma (NASDAQ: CUE) investors approve warrant share issuance and 2026 stock incentive plan - Stock Titan
4.09M-share resale registration from CUE private placement (NASDAQ: CUE) - Stock Titan
Cue Biopharma Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
Cue Biopharma, Inc. 8-K SEC Filing Details: Company Information, Exchange, and Security Data (May 29, 2026) - Minichart
Cue Biopharma, Inc. (CUE) Latest Stock News & Headlines - Yahoo Finance
Cue Biopharma (CUE) director Meehan Viola Mong files initial Form 3 - Stock Titan
Cue Biopharma (CUE) director receives grant of 1,626 stock options at $21.90 - Stock Titan
Cue Biopharma adds two directors as four board members resign - Investing.com UK
Cue Biopharma Streamlines Governance and Strengthens Leadership Team - TipRanks
Cue Biopharma stock falls as four directors resign from board By Investing.com - Investing.com Australia
Cue Biopharma (NASDAQ: CUE) reshapes board, adds new legal and accounting leaders - Stock Titan
Cue Biopharma stock falls as four directors resign from board - Investing.com
Cue Biopharma adds two directors as four board members resign By Investing.com - Investing.com Nigeria
Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution - The Manila Times
Cue Biopharma: Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen Have Resigned From the Bd >CUE - Moomoo
Cue Biopharma Inc stock (US22966J1060): shareholder meeting backs 2026 stock plan and share issuance - AD HOC NEWS
Cue Biopharma Inc stock (US22966J1060): shareholder approval for new stock plan and share issuance - AD HOC NEWS
CUE: All proposals, including warrant issuance and stock plan, were approved by stockholders - TradingView
Cue Biopharma Inc Extraordinary Shareholders Meeting Transcript - GuruFocus
MSN Money - MSN
CUE Q3 2025 Earnings: Narrower-than-Expected Loss Surprises, but Stock Falls on Lack of RevenueEarnings Momentum Score - newsline.com
CUE stock on track for best day in history — why is retail optimistic? - MSN
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):